A Tubular DNA Nanodevice as a siRNA/Chemo-Drug Co-delivery Vehicle for Combined Cancer Therapy
- PMID: 33089613
- DOI: 10.1002/anie.202009842
A Tubular DNA Nanodevice as a siRNA/Chemo-Drug Co-delivery Vehicle for Combined Cancer Therapy
Abstract
Using the DNA origami technique, we constructed a DNA nanodevice functionalized with small interfering RNA (siRNA) within its inner cavity and the chemotherapeutic drug doxorubicin (DOX), intercalated in the DNA duplexes. The incorporation of disulfide bonds allows the triggered mechanical opening and release of siRNA in response to intracellular glutathione (GSH) in tumors to knockdown genes key to cancer progression. Combining RNA interference and chemotherapy, the nanodevice induced potent cytotoxicity and tumor growth inhibition, without observable systematic toxicity. Given its autonomous behavior, exceptional designability, potent antitumor activity and marked biocompatibility, this DNA nanodevice represents a promising strategy for precise drug design for cancer therapy.
Keywords: DNA origami; cancer therapy; drug delivery; nanodevice; siRNA delivery.
© 2020 Wiley-VCH GmbH.
Similar articles
-
DNA nanodevice as a multi-module co-delivery platform for combination cancer immunotherapy.J Colloid Interface Sci. 2024 Aug;667:1-11. doi: 10.1016/j.jcis.2024.04.069. Epub 2024 Apr 13. J Colloid Interface Sci. 2024. PMID: 38615618
-
Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.Colloids Surf B Biointerfaces. 2016 Feb 1;138:60-9. doi: 10.1016/j.colsurfb.2015.11.041. Epub 2015 Nov 25. Colloids Surf B Biointerfaces. 2016. PMID: 26655793
-
Near-infrared light triggered drug delivery system for higher efficacy of combined chemo-photothermal treatment.Acta Biomater. 2017 Mar 15;51:374-392. doi: 10.1016/j.actbio.2016.12.004. Epub 2017 Jan 11. Acta Biomater. 2017. PMID: 28088668
-
Nanoparticle-Based Combination Therapy for Cancer Treatment.Curr Pharm Des. 2015;21(22):3158-66. doi: 10.2174/1381612821666150531165059. Curr Pharm Des. 2015. PMID: 26027570 Review.
-
Role of integrated cancer nanomedicine in overcoming drug resistance.Adv Drug Deliv Rev. 2013 Nov;65(13-14):1784-802. doi: 10.1016/j.addr.2013.07.012. Epub 2013 Jul 21. Adv Drug Deliv Rev. 2013. PMID: 23880506 Review.
Cited by
-
Self-assembled polymeric nanocarrier-mediated co-delivery of metformin and doxorubicin for melanoma therapy.Drug Deliv. 2021 Dec;28(1):594-606. doi: 10.1080/10717544.2021.1898703. Drug Deliv. 2021. PMID: 33729072 Free PMC article.
-
Exploring the diverse biomedical applications of programmable and multifunctional DNA nanomaterials.J Nanobiotechnology. 2023 Aug 23;21(1):290. doi: 10.1186/s12951-023-02071-2. J Nanobiotechnology. 2023. PMID: 37612757 Free PMC article. Review.
-
Emergence of Small Interfering RNA-Based Gene Drugs for Various Diseases.ACS Omega. 2023 Jun 1;8(23):20234-20250. doi: 10.1021/acsomega.3c01703. eCollection 2023 Jun 13. ACS Omega. 2023. PMID: 37323391 Free PMC article. Review.
-
SiRNF8 Delivered by DNA Framework Nucleic Acid Effectively Sensitizes Chemotherapy in Colon Cancer.Int J Nanomedicine. 2024 Jan 6;19:171-188. doi: 10.2147/IJN.S437859. eCollection 2024. Int J Nanomedicine. 2024. PMID: 38204601 Free PMC article.
-
Functionalizing DNA nanostructures for therapeutic applications.Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 Nov;13(6):e1729. doi: 10.1002/wnan.1729. Epub 2021 May 19. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021. PMID: 34008347 Free PMC article. Review.
References
-
- None
-
- S. M. Elbashir, J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, T. Tuschl, Nature 2001, 411, 494-498;
-
- D. Bumcrot, M. Manoharan, V. Koteliansky, D. W. Y. Sah, Nat. Chem. Biol. 2006, 2, 711-719.
-
- None
-
- B. L. Davidson, P. B. McCray, Nat. Rev. Genet. 2011, 12, 329-340;
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical